TECregen has appointed Dr Klaas Zuideveld as chief executive officer to lead the company’s thymus regeneration platform into clinical development. The appointment follows a CHF 10 million seed financing round and the expansion of the company’s board leadership.

Dr Zuideveld brings more than 20 years of experience across pharmaceutical and biotechnology companies, with expertise in translational strategy, clinical development, regulatory execution, and global product approvals. He has also led teams through partnering, financing, and value creation initiatives across multiple therapeutic areas.

“Klaas is a highly experienced leader with a proven ability to translate innovative science into rigorous clinical development programs,” said Dr Bo Rode Hansen, chairman of TECregen. “As TECregen advances its novel approach to restoring thymic function, his leadership will be instrumental in shaping the company’s development strategy and guiding its transition toward the clinic.”

Dr Zuideveld said: “TECregen’s approach to thymus regeneration addresses a central and underexplored mechanism underlying immune dysfunction. With a strong scientific foundation, an expanding pipeline, and committed investor support, the company is well positioned to advance its programs into clinical development and build a platform capable of delivering durable benefit for patients.”

The appointment builds on TECregen’s recent seed financing led by the Boehringer Ingelheim Venture Fund, with participation from LifeSpan Vision Ventures, Carma Fund, EOS BioInnovation, High-Tech Gründerfonds, the JFG Life Sciences Foundation of the University of Basel, and Zurich Cantonal Bank. The round supports the company’s development of thymopoietic biologics designed to rejuvenate thymic epithelial cells (TECs), restore immune function, and strengthen immune resilience.

TECregen’s leadership expansion, including the appointment of Dr Bo Rode Hansen as chairman, positions the company to accelerate its pipeline development and advance thymus rejuvenation programs toward clinical evaluation. The company aims to build a platform of biologics capable of restoring immune competence in patients with compromised immune function.